Observational Study Gemigliptin in Patients Aged ≥ 65 Years With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Registration Number
- NCT05281029
- Lead Sponsor
- LG Chem
- Brief Summary
The aim of this study is to evaluate safety and effectiveness of treatment with gemigliptin for 24 weeks in Korean patients aged ≥ 65 years with type 2 diabetes mellitus in routine clinical settings
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 3000
Inclusion Criteria
- Patients who have been started on gemigliptin in accordance with the approved label and who have signed on the consent form
Exclusion Criteria
- Patients with previous exposure to gemigliptin and current participation in clinical trials
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change from Baseline of HbA1c at 24 weeks Baseline, 24 weeks
- Secondary Outcome Measures
Name Time Method Change from Baseline of HbA1c at 12 weeks Baseline, 12 weeks The rate of subjects who reached the target value of less than 7% (reasonable HbA1c goal) of HbA1c. 24 weeks
Trial Locations
- Locations (1)
Severance Hospital
🇰🇷Seoul, Korea, Republic of